Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:22 UTC |
SPENCER JOHN N JRDirector
|
GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021323 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:21 UTC |
Morgan JayneDirector
|
GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021322 · rdgdoc.xml · derivative · entry 1 Morgan Jayne · CIK 0001959682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:21 UTC |
MCNALLY ROBERT TDirector
|
GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021321 · rdgdoc.xml · derivative · entry 1 MCNALLY ROBERT T · CIK 0001049435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:20 UTC |
Lemerond NicoleDirector
|
GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021320 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:20 UTC |
Kollintzas Dean GDirector
|
GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021319 · rdgdoc.xml · derivative · entry 1 Kollintzas Dean G · CIK 0001378351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:19 UTC |
CHASE RANDAL DDirector
|
GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021317 · rdgdoc.xml · derivative · entry 1 CHASE RANDAL D · CIK 0001078784 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:19 UTC |
Sharkey John W.VP, Business Development
|
GrantStock Option · Derivative | 17,600 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021316 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2036-06-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:18 UTC | GrantStock Option · Derivative | 17,600 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021315 · rdgdoc.xml · derivative · entry 1 Reynolds Mark · CIK 0001298237 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2036-06-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
|
| June 17, 2026 Filed Jun 22, 2026 20:18 UTC |
NEWMAN MARK JChief Scientific Officer
|
GrantStock Option · Derivative | 17,600 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021314 · rdgdoc.xml · derivative · entry 1 NEWMAN MARK J · CIK 0001242123 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2036-06-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:17 UTC |
McKee Kelly T. Jr.Chief Medical Officer
|
GrantStock Option · Derivative | 17,600 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021312 · rdgdoc.xml · derivative · entry 1 McKee Kelly T. Jr. · CIK 0001903889 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2036-06-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:16 UTC |
DODD DAVID ADirector · President, CEO
|
GrantStock Option · Derivative | 29,300 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021311 · rdgdoc.xml · derivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,300 Underlying: Common Stock · 29,300 shares Expires 2036-06-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 13:11 UTC |
SPENCER JOHN N JRDirector
|
PurchaseCommon Stock | 10,000 | $0.55 | $5,498.00 |
DisclosureSEC source: 0001437749-25-031314 · rdgdoc.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,402 Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 19:13 UTC |
McKee Kelly T. Jr.Chief Medical Officer
|
PurchaseCommon Stock | 1,107 | $0.67 | $741.69 |
DisclosureSEC source: 0001437749-25-025690 · rdgdoc.xml · nonDerivative · entry 1 McKee Kelly T. Jr. · CIK 0001903889 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,494 Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:51 UTC |
Lemerond NicoleDirector
|
GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019644 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:50 UTC |
CHASE RANDAL DDirector
|
GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019642 · rdgdoc.xml · derivative · entry 1 CHASE RANDAL D · CIK 0001078784 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:49 UTC |
Kollintzas Dean GDirector
|
GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019640 · rdgdoc.xml · derivative · entry 1 Kollintzas Dean G · CIK 0001378351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:46 UTC |
Morgan JayneDirector
|
GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019636 · rdgdoc.xml · derivative · entry 1 Morgan Jayne · CIK 0001959682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:48 UTC |
MCNALLY ROBERT TDirector
|
GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019638 · rdgdoc.xml · derivative · entry 1 MCNALLY ROBERT T · CIK 0001049435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:42 UTC |
NEWMAN MARK JChief Scientific Officer
|
GrantStock Option · Derivative | 70,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019632 · rdgdoc.xml · derivative · entry 1 NEWMAN MARK J · CIK 0001242123 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-01-02 F2 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:45 UTC |
SPENCER JOHN N JRDirector
|
GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019634 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:41 UTC |
McKee Kelly T. Jr.Chief Medical Officer
|
GrantStock Option · Derivative | 70,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019630 · rdgdoc.xml · derivative · entry 1 McKee Kelly T. Jr. · CIK 0001903889 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-01-02 F2 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:39 UTC |
Sharkey John W.VP, Business Development
|
GrantStock Option · Derivative | 70,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019628 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-01-02 F2 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:38 UTC | GrantStock Option · Derivative | 70,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019626 · rdgdoc.xml · derivative · entry 1 Reynolds Mark · CIK 0001298237 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-01-02 F2 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
|
| June 05, 2025 Filed Jun 6, 2025 13:35 UTC |
DODD DAVID ADirector · President, CEO
|
GrantStock Option · Derivative | 185,500 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019624 · rdgdoc.xml · derivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,500 Underlying: Common Stock · 185,500 shares Expires 2035-01-02 F2 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| April 10, 2025 Filed Apr 10, 2025 20:01 UTC |
Sharkey John W.VP, Business Development
|
PurchaseCommon Stock | 6,000 | $0.99 | $5,940.00 |
DisclosureSEC source: 0001437749-25-011658 · rdgdoc.xml · nonDerivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,191 Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 17:23 UTC |
SPENCER JOHN N JRDirector
|
PurchaseCommon Stock | 10,000 | $0.98 | $9,800.00 |
DisclosureSEC source: 0001437749-25-011750 · rdgdoc.xml · nonDerivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,402 Read SEC document |
| April 01, 2025 Filed Apr 1, 2025 20:46 UTC |
DODD DAVID ADirector · President, CEO
|
PurchaseCommon Stock | 10,000 | $1.08 | $10,800.00 |
DisclosureSEC source: 0001437749-25-010482 · rdgdoc.xml · nonDerivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,661 Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 20:04 UTC | PurchaseCommon Stock | 6,800 | $1.08 | $7,343.32 |
DisclosureSEC source: 0001437749-25-010179 · rdgdoc.xml · nonDerivative · entry 1 Reynolds Mark · CIK 0001298237 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,013 Read SEC document |
|
| August 12, 2024 Filed Aug 14, 2024 20:12 UTC |
DODD DAVID ADirector · President, CEO
|
GrantStock Option · Derivative | 35,000 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026813 · rdgdoc.xml · derivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:11 UTC |
McKee Kelly T. Jr.Chief Medical Officer
|
GrantStock Option · Derivative | 15,700 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026809 · rdgdoc.xml · derivative · entry 1 McKee Kelly T. Jr. · CIK 0001903889 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-08-12 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:10 UTC |
NEWMAN MARK JChief Scientific Officer
|
GrantStock Option · Derivative | 15,700 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026804 · rdgdoc.xml · derivative · entry 1 NEWMAN MARK J · CIK 0001242123 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-08-12 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:10 UTC | GrantStock Option · Derivative | 15,700 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026802 · rdgdoc.xml · derivative · entry 1 Reynolds Mark · CIK 0001298237 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-08-12 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
|
| August 12, 2024 Filed Aug 14, 2024 20:09 UTC |
Sharkey John W.VP, Business Development
|
GrantStock Option · Derivative | 15,700 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026800 · rdgdoc.xml · derivative · entry 1 Sharkey John W. · CIK 0001515991 · VP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-08-12 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments on the first three anniversary dates of the grant. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:09 UTC |
CHASE RANDAL DDirector
|
GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026798 · rdgdoc.xml · derivative · entry 1 CHASE RANDAL D · CIK 0001078784 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:08 UTC |
Kollintzas Dean GDirector
|
GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026793 · rdgdoc.xml · derivative · entry 1 Kollintzas Dean G · CIK 0001378351 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:07 UTC |
Lemerond NicoleDirector
|
GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026791 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:07 UTC |
MCNALLY ROBERT TDirector
|
GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026788 · rdgdoc.xml · derivative · entry 1 MCNALLY ROBERT T · CIK 0001049435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:06 UTC |
Morgan JayneDirector
|
GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026787 · rdgdoc.xml · derivative · entry 1 Morgan Jayne · CIK 0001959682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:06 UTC |
SPENCER JOHN N JRDirector
|
GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026786 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 12:47 UTC |
DODD DAVID ADirector · President, CEO
|
PurchaseCommon Stock | 8,000 | $1.95 | $15,600.00 |
DisclosureSEC source: 0001437749-24-025953 · rdgdoc.xml · nonDerivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,661 Read SEC document |
| February 22, 2024 Filed Feb 22, 2024 21:41 UTC |
DODD DAVID ADirector · President, CEO
|
PurchaseCommon Stock | 8,209 | $2.27 | $18,663.16 |
DisclosureSEC source: 0001437749-24-005209 · rdgdoc.xml · nonDerivative · entry 2 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,661 Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 21:41 UTC |
DODD DAVID ADirector · President, CEO
|
PurchaseCommon Stock | 520 | $2.15 | $1,118.00 |
DisclosureSEC source: 0001437749-24-005209 · rdgdoc.xml · nonDerivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,452 Read SEC document |
| February 07, 2024 Filed Feb 7, 2024 21:43 UTC | PurchaseCommon Stock | 2,000 | $2.77 | $5,540.00 |
DisclosureSEC source: 0001437749-24-003380 · rdgdoc.xml · nonDerivative · entry 1 Reynolds Mark · CIK 0001298237 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,213 Read SEC document |
|
| December 22, 2023 Filed Dec 26, 2023 20:51 UTC |
McKee Kelly T. Jr.Chief Medical Officer
|
PurchaseCommon Stock | 6,944 | $0.36 | $2,499.84 |
DisclosureSEC source: 0001437749-23-035306 · rdgdoc.xml · nonDerivative · entry 1 McKee Kelly T. Jr. · CIK 0001903889 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,782 Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 20:33 UTC |
McKee Kelly T. Jr.Chief Medical Officer
|
PurchaseCommon Stock | 9,653 | $0.52 | $5,019.56 |
DisclosureSEC source: 0001437749-23-026935 · rdgdoc.xml · nonDerivative · entry 1 McKee Kelly T. Jr. · CIK 0001903889 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,838 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 20:05 UTC |
DODD DAVID ADirector · President, CEO
|
PurchaseCommon Stock | 35,087 | $0.57 | $19,999.59 |
DisclosureSEC source: 0001437749-23-024763 · rdgdoc.xml · nonDerivative · entry 1 DODD DAVID A · CIK 0001193607 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,957 Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 12:39 UTC | PurchaseCommon Stock | 10,000 | $0.52 | $5,179.00 |
DisclosureSEC source: 0001437749-23-024227 · rdgdoc.xml · nonDerivative · entry 1 Reynolds Mark · CIK 0001298237 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,184 Read SEC document |
|
| August 01, 2023 Filed Aug 14, 2023 20:53 UTC |
SPENCER JOHN N JRDirector
|
GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001437749-23-023746 · rdgdoc.xml · derivative · entry 1 SPENCER JOHN N JR · CIK 0001270555 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-07 F1 · date: This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| August 01, 2023 Filed Aug 14, 2023 20:53 UTC |
Morgan JayneDirector
|
GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001437749-23-023745 · rdgdoc.xml · derivative · entry 1 Morgan Jayne · CIK 0001959682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-07 F1 · date: This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| August 01, 2023 Filed Aug 14, 2023 20:52 UTC |
MCNALLY ROBERT TDirector
|
GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001437749-23-023744 · rdgdoc.xml · derivative · entry 1 MCNALLY ROBERT T · CIK 0001049435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-07 F1 · date: This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.